Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

Journal of Clinical Pathology

Volumn 53, Issue 5, 2000, Pages 374-381

  Wang, S ^a   Saboorian, M H ^a   Frenkel, E ^a   Hynan, L ^b   Gokaslan, S T ^c   Ashfaq, R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NONE

Author keywords

Breast cancer; Fluorescence in situ hybridisation; Her 2 neu

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FORMALDEHYDE; MONOCLONAL ANTIBODY; ONCOPROTEIN; PARAFFIN; POLYCLONAL ANTIBODY; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; EVALUATION STUDIES; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 0034018946     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.53.5.374     Document Type: Article

References (25)

1. 1 Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997;410:83-6.
2. 2 Reese D, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells (Dayt) 1997; 15:1-8.
3. 3 Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-81.
4. 4 Slamon DJ, Godolphin W, Jones LA, et al. Studies of the Her/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
5. 5 Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808.
6. 6 Naber SP, Tsutsumi Y, Yin S, et al. Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma. Am J Clin Pathol 1990;94: 125-36.
7. 7 Kallioniemi O-P, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992;89:5321-5.
8. 8 McGann AH, Dervan PA, O'Regan M, et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991;51:3296-303.
9. 9 Gusterson, BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10:1049-56.
10. 10 Quenel N, Wafflart J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995;35:283-91.
11. 11 Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
12. 12 Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
13. 13 Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive breast cancer. N Engl J Med 1994;330:1260-6.
14. 14 Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
15. 15 Baselga, J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of Paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
16. 16 Slamon DJ, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER-2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomized, multinational controlled phase III trial [abstract 377]. Proceedings of the American Society of Clinical Oncology 1998;17:98A.
17. 17 Press MF, Hung G, Godolphin W, et al. Sensitivity of HER2/neu antibodies in archival tissue samples: potential source of errors in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-77.
18. 18 Ashfaq R, Frenkel E, Saliger F, et al. Her-2/neu oncogene overexpression: comparison of immunohistochemistry (IHC) with fluorescent in situ hybridization assay (FISH) [abstract 70]. Mod Pathol 1999;12:15A.
19. 19 Jimenez RE, Wallis T, Tabaczka P, et al. Fluorescent in situ hybridization (FISH) vs immunohistochemistry (IHC) for determination of Her2/neu status in breast cancer [abstract 116]. Mod Pathol 1999;12:23A.
20. 20 Jacobs TW, Barnes M, Yaziji H, et al. Her2/neu protein expression in breast cancer determined by immunohistochemistry (IHC): a study of inter-laboratory agreement [abstract 113]. Mod Pathol 1999;12:23A.
21. 21 Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
22. 22 Roche PC, Ingle JN. Increased HER2 with US Food and Drug Administration-approved antibody. J Clin Oncol 1999;17:434-435.
23. 23 Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999;17:1974-82.
24. 24 Jacobs TW, Gown AM, Yaziji H, et al. Specificity of Hercep Test in determining HER-2/neu status of breast cancers using the United States Food and Drug Administrationapproved scoring system. J Clin Oncol 1999;17:1983-7.
25. 25 Jimenez RE, Wallis T, Tabasczka P, et al. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.